Dbv Technologies S A SEC Filings

DBV Technologies S.A. (DBVT) reported insider transactions by its Chief Medical Officer on a Form 4. On November 20, 2025, the officer sold 6,496 ordinary shares at $2.88 per share, followed by a sale of 1,624 ordinary shares at $2.77 per share on November 21, 2025, mainly to cover tax withholding tied to vesting restricted stock units. After these sales, the officer held 101,529 ordinary shares directly, which then increased to 145,529 ordinary shares after the grant of new equity.

On November 21, 2025, the officer received 44,000 restricted stock units (RSUs), each representing one ordinary share, and an employee stock option for 253,000 ordinary shares with an exercise price of $2.90. Both the RSUs and options vest in four equal annual installments starting on November 21, 2026, subject to continued service. The filing notes that each American Depositary Share currently represents five ordinary shares.

DBV Technologies S.A. (DBVT) reported a Form 4 for its Chief Financial Officer, Virginie Boucinha, reflecting new equity compensation granted on 11/21/2025. She acquired 32,000 ordinary shares at a price of $0, representing ordinary shares underlying a restricted stock unit (RSU) award, bringing her directly held ordinary shares to 70,000. She also received an employee stock option for 192,000 ordinary shares with an exercise price of $2.9 and an expiration date of 11/21/2035. Both the RSUs and the option vest in four equal annual installments starting on November 21, 2026, contingent on her continued service with the company.

DBV Technologies S.A. (DBVT) reported an equity award to its Chief Commercial Officer on a Form 4 insider filing. On November 21, 2025, the officer received 55,000 ordinary shares through a restricted stock unit (RSU) award and 316,250 employee stock options with an exercise price of $2.9 per share. Both the RSUs and options vest in four equal annual installments starting on November 21, 2026, contingent on continued service. The options expire on November 21, 2035. The ordinary shares may be represented by American Depositary Shares, with each ADS currently representing five ordinary shares.

DBV Technologies S.A. (DBVT) reported a Form 4 insider transaction for its Chief Executive Officer and director. On 11/21/2025, the reporting person received an employee stock option grant to buy 964,000 ordinary shares of DBV Technologies.

The option has an exercise price of $2.9 per share, stated in U.S. dollars and based on converting euros at an exchange rate of $1.15154 to €1.00 as of November 21, 2025. These options are exercisable until 11/21/2035 and were fully reported as directly owned.

The option vests in four equal annual installments starting on November 21, 2026, as long as the executive continues to provide service through each vesting date. This filing reflects an equity-based compensation award rather than an open-market purchase or sale of shares.

DBV Technologies S.A. (DBVT) reported an insider ownership update via Form 3. The reporting person, who serves as Chief Commercial Officer, filed as a single reporting person and stated no securities are beneficially owned. The event date is 11/03/2025. This filing establishes the officer’s initial ownership position, indicating no non-derivative or derivative holdings at the time referenced.

DBV Technologies appointed Philina Lee, Ph.D., to its Board of Directors effective October 30, 2025, filling the vacancy created by the resignation of Daniel Soland. She will also join the Compensation Committee in his place, with her appointment to be submitted to a shareholder vote at the next annual Ordinary and Extraordinary General Meeting.

Lee brings senior commercial and portfolio leadership experience from Blueprint Medicines, Sanofi, Genzyme and Algeta, and prior board service at Fusion Pharmaceuticals. Under the company’s non-employee director compensation policy, she will receive a fixed annual retainer of €100,000 and €5,000 per year for Compensation Committee service.

DBV Technologies S.A. (DBVT) furnished an 8‑K announcing a press release with financial results and business highlights for the quarter ended September 30, 2025. The press release is included as Exhibit 99.1. The information under Item 2.02 is being furnished, not filed, and is not subject to Section 18 liability, nor incorporated by reference except as expressly set forth.

DBV Technologies (DBVT) reported Q3 results and liquidity updates. Cash and cash equivalents were $69.8 million as of September 30, 2025. The company posted a Q3 net loss of $33.2 million and a nine‑month net loss of $102.1 million, driven mainly by R&D spending for the Viaskin Peanut program.

DBV closed a $125.5 million financing in April 2025 and established an ATM program of up to $150.0 million; after quarter‑end it sold 2,307,692 ADSs for gross proceeds of about $30 million on October 6, 2025. The company estimates its cash runway extends into the third quarter of 2026, yet it states these conditions raise substantial doubt about its ability to continue as a going concern. Operating cash use was $86.0 million for the first nine months; financing cash inflows were $117.1 million.

Clinical and regulatory milestones remain central: VITESSE Phase 3 topline results in children 4–7 are anticipated in the fourth quarter of 2025, and up to $181.4 million in additional gross proceeds may be received if warrants are exercised, subject to conditions. As of October 27, 2025, 169,113,619 ordinary shares were outstanding including treasury shares.